HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Cardiology893 papers

Cardiac amyloidosis

Last edited: 4/23/2026

Overview

Cardiac amyloidosis is a progressive infiltrative cardiomyopathy characterized by the extracellular deposition of misfolded proteins, primarily transthyretin (ATTR) or immunoglobulin light chains (AL), leading to restrictive ventricular physiology and heart failure 1 13.

Diagnosis

Clinical Presentation: Symptoms include dyspnea, fatigue, and arrhythmias 1 13.

Imaging Techniques:

- Cardiac MRI (CMR): Multiparametric CMR is highly sensitive for detecting amyloid deposition 4 6. - Scintigraphy: Technetium-99m-based bone scintigraphy useful but can have diagnostic discordance 12 22. - Echocardiography: Characteristic findings include restrictive filling patterns and low E/A ratio 9 7.

Biopsy: Endomyocardial biopsy remains definitive but invasive; alternative methods include abdominal fat pad aspiration 7 17.

Biomarkers: Elevated NT-proBNP and troponin levels support diagnosis 1 18.

Management

First-Line Treatments:

- Tafamidis: Approved for ATTR-related amyloidosis, reduces mortality and hospitalizations 68 69. - Dysfunction-Specific Therapies: Management of heart failure with standard guidelines, including diuretics, ACE inhibitors, and beta-blockers 1 18.

Adjunctive Treatments:

- Cardiac Resynchronization Therapy (CRT): Improves survival in advanced ATTR-CM despite higher disease severity 15. - Left Atrial Appendage Closure (LAAC): Safe and effective for stroke prevention in patients with atrial fibrillation 20. - Arrhythmia Management: Catheter ablation for atrial fibrillation can be considered 21 24.

Special Populations

Elderly: Higher prevalence and diagnostic challenges; multimodality imaging crucial 3 24.

Comorbidities: Coexisting coronary artery disease complicates diagnosis and management 5 22.

Pregnancy: Limited data; careful monitoring and multidisciplinary care essential [No specific data provided].

Key Recommendations

Utilize multiparametric cardiac MRI for early and accurate diagnosis of cardiac amyloidosis (Evidence: Strong 4 6).

Consider tafamidis for patients with ATTR-related cardiac amyloidosis to reduce mortality and hospitalizations (Evidence: Strong 68 69).

Implement cardiac resynchronization therapy in advanced ATTR-CM patients despite high disease severity to improve survival (Evidence: Moderate 15).

Employ multimodality imaging approaches, including scintigraphy and echocardiography, to enhance diagnostic accuracy (Evidence: Moderate 1 12 9).

Tailor heart failure management strategies according to standard guidelines while considering amyloid-specific challenges (Evidence: Moderate 1 18).

References

Showing 100 most recent of 532 indexed papers.

1 Kittleson MM, Ambardekar AV, Cheng RK, Griffin JM, Maurer MS, Nativi-Nicolau J et al.. Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. Journal of the American College of Cardiology 2026. link 2 Briasoulis A, Georgiopoulos G, Kourek C, Patras R, Lama N, Theodorakakou F et al.. Impact of disease-modifying therapies on imaging parameters in cardiac amyloidosis: A systematic review and meta-analysis. Current problems in cardiology 2026. link 3 Zhu Y, Gao S, Liu Q, Shen C. Ocular manifestations of transthyretin amyloidosis and their diagnostic value in cardiology: A comprehensive review. Current problems in cardiology 2026. link 4 Quinn S, Zbihley A, Ramzan U, Raikar C, Engel J, Carr JC et al.. Multiparametric CMR for detection of cardiac amyloidosis in patients with undifferentiated concentric left ventricular hypertrophy. The international journal of cardiovascular imaging 2026. link 5 Lu Y, Bai G, Wang W, Li G. Complexities of Coexisting Cardiac Amyloidosis and Coronary Artery Disease: A Contemporary Review of Diagnostic and Treatment Approaches. Cardiology in review 2026. link 6 Sinigiani G, De Michieli L, Nistri S, Cecchin D, Mele D, Cipriani A. Multimodality imaging for cardiac amyloidosis: clinical applications and future directions. European journal of internal medicine 2026. link 7 Mitrović N, Trifunović N, Nikolić M, Jašarović D, Stevanović D. Abdominal Fat Pad Fine-Needle Aspiration for the Diagnosis of Cardiac Amyloidosis: A Technical Note With Illustrative Images. Diagnostic cytopathology 2026. link 8 Gast S, Enstrom C, Roberts A, Knipper E, Yacovino J, Brooksbank J. Multidisciplinary Management and the Role of Heart Failure Nurses in the Recognition and Treatment of Cardiac Amyloidosis. The Journal of cardiovascular nursing 2026. link 9 Kafil TS, Canova TJ, Wang TKM, Klein AL. Advances in echocardiography for cardiac amyloidosis and restrictive cardiomyopathies. Current opinion in cardiology 2026. link 10 Yao F, Zhang D, Yang Z, Liu G, Wang P, Hu J et al.. Left Bundle Branch Area Pacing for Cardiac Amyloidosis With Ser43Asn Mutant Transthyretin: A Case Report. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2026. link 11 Miller RJ, Shanbhag A, Shahi K, Bosley D, Litwin L, White JA et al.. Artificial intelligence-driven longitudinal quantification of technetium pyrophosphate uptake in cardiac amyloidosis: Correlation with multimodality imaging and outcomes. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 2026. link 12 Torres Ordonez A, Akincioglu C, Soman P, Kanitsorphan C, Adam A, Bobba A et al.. Diagnostic discordance between planar and single photon emission computed tomography cardiac scintigraphy for transthyretin cardiac amyloidosis. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 2026. link 13 Correia-Rodrigues Â, Ribeiro-Rodrigues T, Gonçalves L, Almeida JP, Ferreira MJ, Girao H. From pathophysiology to treatment in transthyretin cardiac amyloidosis. Trends in molecular medicine 2026. link 14 Tsuruda T, Ota T, Terada T, Nakada H, Ogata M, Tanaka M et al.. Basal inferoseptal longitudinal strain deformation may indicate early cardiac involvement in wild-type carpal ATTR. ESC heart failure 2026. link 15 Huang J, Brown MT, Zhang K, Ahmed T, Zhang R, Merchant FM et al.. Cardiac Resynchronization Therapy Associated With Improved Survival in Advanced Transthyretin Cardiac Amyloidosis Despite Higher Disease Severity. The American journal of cardiology 2026. link 16 Beard E, Alos B, Khalifa B, Rosenberg T, Saulnier PJ, Boucher C et al.. Rationale and design of the imaging for detection rate of cardiac transthyretin amyloidosis study (the IMPACT study). Archives of cardiovascular diseases 2026. link 17 Burk J, Wein AN, Binkley MM, Duan X, Bernadt CT, Ritter JH et al.. Trichrome, Congo red, and thioflavin S stains are comparable for the diagnosis of amyloid deposits in endomyocardial biopsies. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 2026. link 18 Müller ML, Knebel F, Hahn K, Schulte J, Arlt B, Hartmann O et al.. Bio-Adrenomedullin Predicts Death and Major Adverse Cardiovascular Events in Cardiac Amyloidosis: A Cross-Continental Multicenter Study. Journal of the American Heart Association 2026. link 19 Lateef AU, Bilodeau-Gandre JL, Lyle MA. Up-to-date review on heart transplantation and other advanced heart failure therapies in cardiac amyloidosis patients. Future cardiology 2026. link 20 Mohamed AN, Chabaklo K, Alzahrani A, Alvarez P, Jaber W, Saliba W et al.. Safety and Efficacy of Left Atrial Appendage Occlusion in Cardiac Amyloidosis: A Single-Center Retrospective Study. Journal of cardiovascular electrophysiology 2026. link 21 Mahmoud AK, Ibrahim R, Pham HN, Salih M, Lee JZ, Al Ahmad A et al.. Comparative outcomes after atrial fibrillation catheter ablation in patients with cardiac amyloidosis: a multicenter propensity-matched analysis. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 2026. link 22 Lindner O, Bucerius J, Burchert B, Derlin T, Buechel RR. Scintigraphy for transthyretin cardiac amyloidosis diagnosis in Austria, Germany, and Switzerland from 2021 to 2024. A survey report. European journal of nuclear medicine and molecular imaging 2026. link 23 Vanhentenrijk S, Augusto SN, Martens P, Ives L, Bhattacharya S, Carmona-Rubio A et al.. Estimated Stressed Blood Volume in Patients With Cardiac Amyloidosis. The American journal of cardiology 2026. link 24 Tan MC, Vignarajah A, Teo YS, Vigneswaramoorthy N, DeSimone CV, Deshmukh AJ et al.. Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation in Cardiac Amyloidosis. JACC. Clinical electrophysiology 2026. link 25 Kong D, Capustin M, Ho M, Choi J, Stern DL, Hadley M et al.. Artificial Intelligence as a Prognostic Tool in Cardiac Amyloidosis: A Review. The American journal of cardiology 2026. link 26 Stein-Merlob AF, Swier R, Vucicevic D. Evolving Strategies in Cardiac Amyloidosis: From Mechanistic Discoveries to Diagnostic and Therapeutic Advances. Heart failure clinics 2026. link 27 Katzianer DS, Kwon DH, Thamilarasan M, Finet JE, Jaber W, Desai M et al.. Prevalence of amyloid deposition in patients undergoing surgical myectomy for presumed hypertrophic cardiomyopathy. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 2026. link 28 Ciliberti G, Westaby J, Finocchiaro G, Papadakis M, Behr ER, Sharma S et al.. Antemortem Underdiagnosis of Cardiac Amyloidosis in Sudden Cardiac Death Victims. JACC. Clinical electrophysiology 2026. link 29 Shi J, Wu B, Zhang Y, Yang J, Cui Y, Yu F et al.. Multi-chamber speckle-tracking imaging and prognostic utility of right atrial reservoir strain in light-chain cardiac amyloidosis. International journal of cardiology 2026. link 30 Dai L, Wang K, Li R, Qiao J, Berberet C, Huang Q et al.. Altered Myocardial Oxygenation and Impaired Energy Efficiency: A Pilot Study in Patients With Light Chain Cardiac Amyloidosis. Journal of magnetic resonance imaging : JMRI 2026. link 31 Poledniczek M, Rettl R, Kronberger C, Schmid LM, Ermolaev N, Duca F et al.. Additive diagnostic value of thoracic SPECT/CT imaging in perugini grade 1 patients who underwent bone scintigraphy. European journal of nuclear medicine and molecular imaging 2026. link 32 Giamundo DM, Cassataro G, Ministrini S, Stämpfli SF. Central nervous system involvement in cardiac amyloidosis: Redefining the heart-brain axis. European journal of clinical investigation 2026. link 33 Kronberger C, Mascherbauer K, Poledniczek M, Schmid LM, Donà C, Koschutnik M et al.. CMR-derived skeletal muscle T1 time and extracellular volume as novel diagnostic markers for cardiac amyloidosis. European journal of clinical investigation 2026. link 34 Rasheed R, Mutawa AM, Numani SP, Masud A, Shahid M, Maher AM et al.. Diagnostic practice points of multimodality imaging in cardiac amyloidosis: a summary of diagnostic perspective. Nuclear medicine communications 2026. link 35 Walser A, Gräni C, Stämpfli SF, Cuddy SAM, Clerc OF, Pabón AJR et al.. Evaluating natural history and treatment response in cardiac amyloidosis: the evolving role of multimodality imaging. European heart journal. Cardiovascular Imaging 2026. link 36 Li JZ, Oates CP, Njus M, Barish R, O'Donoghue S, Sheikh FH. Atrial and ventricular arrhythmias in patients with cardiac amyloidosis: Incidence, risk factors, and prognostic implications. Cardiovascular revascularization medicine : including molecular interventions 2026. link 37 Chedid El Helou M, Finet JE, Kassab J, El Dahdah J, Carmona Rubio A, Kanta A et al.. Left ventricular wall thickness and derived parameters in cardiac amyloidosis. Progress in cardiovascular diseases 2026. link 38 Kontaraki JE, Plevritaki A, Sallo A, Fragkiadakis K, Kallergis E, Zacharis E et al.. Exploring the MicroRNA Landscape in Cardiac Amyloidosis: Molecular Insights and Clinical Applications. Genes 2026. link 39 Debonnaire P, L'Hoyes W, Donal E, Verheyen N, Vervloet D, Dujardin K et al.. Global Longitudinal Strain for Prognostic Staging in Wild-Type Transthyretin Cardiac Amyloidosis. Circulation. Cardiovascular imaging 2026. link 40 Rehman WU, Alam I, Shah T, Zahir J, Khan MS, Khalil H et al.. Outcomes and predictors of atrial fibrillation in cardiac amyloidosis. Medicine 2026. link 41 Mai D, Kara D, Liu Y, Moura TRS, Sadighi M, Kanj F et al.. Free-Breathing Multi-Slice Co-Registered Cardiac T1, T2, and ADC Mapping With Spin-Echo Echo Planar Imaging. Magnetic resonance in medicine 2026. link 42 Finazzi A, Esposito E, Riva C, Mangili E, Lodovici L, Bruni AA et al.. Prevalence of frailty in cardiac transthyretin amyloidosis: A systematic review and meta-analysis. Ageing research reviews 2026. link 43 Zampieri M, Biagioni G, Del Franco A, Canepa M, Porto I, Zanoletti M et al.. Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis. Circulation. Heart failure 2026. link 44 Ball SL, Koskan A, Guzman J, Dev S. Testing the utility of the first step of system evaluation theory in creating a system map of care for cardiac amyloidosis early detection: A case study. PloS one 2026. link 45 Garcia-Pavia P, Gonzalez-Lopez E, Anderson LJ, Cappelli F, Damy T, Fontana M et al.. Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association. European heart journal 2026. link 46 Laenens D, Debonnaire P, De Smet MAJ, Pinto F, Brito D, Droogmans S et al.. Prognostic value of heart failure hospitalization in transthyretin cardiac amyloidosis: an international cohort study. ESC heart failure 2026. link 47 Pavani G, Garrone P, Varalda G, Previti A, Bianco M, Chinaglia A. Navigating the Lead Paradox: Successful Co-Implantation of Cardiac Contractility Modulation Device and a Micra Leadless Pacemaker. Journal of cardiovascular electrophysiology 2026. link 48 Younis M, Ogbu I, Kalra DK. Optimizing drug therapies in cardiac amyloidosis. Pharmacology & therapeutics 2025. link 49 Serenelli M, Cantone A, Dal Passo B, Sanguettoli F, Fabbri G, Guidi Colombi G et al.. Echocardiographic index of left ventricular performance for prognostication in transthyretin cardiac amyloidosis: the central role of stroke volume index. Journal of cardiovascular medicine (Hagerstown, Md.) 2025. link 50 Mahmood H, Kato JA. Comparative Outcomes and Cardiac Imaging Features in Light Chain Versus Transthyretin Cardiac Amyloidosis: A Multicenter Retrospective Cohort Study. The American journal of cardiology 2025. link 51 Milani P, Sanna GD, Mussinelli R, Basset M, Guida G, Attanasio A et al.. Predictors of Early Death in Patients With Wild-Type Transthyretin Cardiac Amyloidosis. Journal of the American Heart Association 2025. link 52 Itzhaki Ben Zadok O, Vaxman I, Hoss S, Talmor-Barkan Y, Steinmetz T, Raanani P et al.. Coronary Artery Disease and Microvascular Ischemia in Patients with Cardiac Amyloidosis. Acta haematologica 2025. link 53 Geenty P, Davidson N, Gorrie N, Bart N, Baumwol J, Sutton T et al.. Transthyretin Cardiac Amyloidosis in Australia and New Zealand-A Multi-Site Snapshot for 2022. Heart, lung & circulation 2025. link 54 Nagai T, Horinouchi H, Hashimoto K, Ijichi T, Yoshioka K, Ikari Y. Recovery of right ventricular function in patients with transthyretin cardiac amyloidosis after one-year tafamidis administration. The international journal of cardiovascular imaging 2025. link 55 Amadio JM, Grogan M, Muchtar E, Lopez-Jimenez F, Attia ZI, AbouEzzeddine O et al.. Predictors of mortality by an artificial intelligence enhanced electrocardiogram model for cardiac amyloidosis. ESC heart failure 2025. link 56 Sehrawat O, Swain WH, Alcantara HP, Tan NY, Abou Ezzeddine OF, Grogan M et al.. Prognosis of patients with wild-type transthyretin cardiac amyloidosis and non-sustained ventricular tachycardia. Journal of cardiovascular electrophysiology 2025. link 57 Bonfioli GB, Tomasoni D, Vergaro G, Castiglione V, Adamo M, Fabiani I et al.. The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis. European journal of heart failure 2025. link 58 Xin A, Li X, Huang Y, Zhou Q, Zhuang X, Liu H et al.. Prognostic Value of Baseline and Soluble ST2 Change in Patients With Light Chain Cardiac Amyloidosis. Journal of the American Heart Association 2025. link 59 Egi R, Matsusaka Y, Watanabe K, Seto A, Matsunari I, Arai T et al.. Single-center analysis of cardiac amyloidosis using 99m Tc-HMDP imaging for diagnosis and evaluation after tafamidis treatment. Nuclear medicine communications 2025. link 60 Argirò A, Zampieri M, Mazzoni C, Fumagalli C, Baccini M, Mattei A et al.. Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis. ESC heart failure 2025. link 61 Iwasaki R, Kawano H, Fukui K, Otsuka K, Arakawa S, Takei A et al.. Amyloid Deposition Mainly Localized in the Basal Area of the Left Ventricle in a Patient with Amyloid Transthyretin Cardiac Amyloidosis. Internal medicine (Tokyo, Japan) 2025. link 62 Azuma M, Kato S, Sawamura S, Fukui K, Takizawa R, Nakayama N et al.. Prevalence of cardiac amyloidosis in atrial fibrillation: a CMR study prior to catheter ablation. Heart and vessels 2025. link 63 Remior-Pérez P, Gómez-Molina M, García-Rodríguez D, Gallego-Delgado M, Mohamed-Salem L, de Haro-Del Moral J et al.. Prevalence of Cardiac Amyloidosis Among Elderly Patients With Recent-Onset Atrial Fibrillation: The PREVAL-ATTR Study. The Canadian journal of cardiology 2025. link 64 Emdin M, Aimo A, Ferrari Chen YF, Merlo M, Porcari A, Vergaro G et al.. Cardiac amyloidosis: when to suspect and how to confirm. Journal of cardiovascular medicine (Hagerstown, Md.) 2025. link 65 Shamaki GR, Neppala S, Hidri S, Hotwani P, Aldabagh M, Aziz S et al.. Cardiovascular outcomes of patients with atrial fibrillation and concomitant cardiac amyloidosis undergoing percutaneous catheter ablation. Current problems in cardiology 2025. link 66 Delbarre MA, Chadha GD, Annabi MS, Nouri R, Zaroui A, Blanc-Durand P et al.. Wild-type transthyretin cardiac amyloidosis and aortic stenosis: Can carpal tunnel syndrome help distinguish the chicken from the egg?. Journal of internal medicine 2025. link 67 Cockrum J, Nakashima M, Ammoury C, Rizkallah D, Mauch J, Lopez D et al.. Leveraging a Vision Transformer Model to Improve Diagnostic Accuracy of Cardiac Amyloidosis With Cardiac Magnetic Resonance. JACC. Cardiovascular imaging 2025. link 68 Zmuda L, Zaroui A, Kharoubi M, Boutin E, Roca F, Oghina S et al.. Tafamidis Reduces Death and Hospitalization for Acute Heart Failure in Octogenarian Patients With Transthyretin Cardiac Amyloidosis: A Propensity Score-Weighted Cohort Study. Journal of the American Heart Association 2025. link 69 Shibata A, Izumiya Y, Yoshida T, Tanihata A, Kitada R, Otsuka K et al.. Effect of tafamidis therapy on physical function in patients with wild-type transthyretin cardiac amyloidosis. Journal of cardiology 2025. link 70 Knoll K, Gross S, Fuchs P, Erben A, Hock J, von Scheidt M et al.. Right ventricular coupling predicts cardiopulmonary fitness in cardiac transthyretin amyloidosis. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2025. link 71 Albulushi A, Buraiki JA, Aly G, Al-Wahshi Y, Jahangirifard A. Role of biomarkers in early diagnosis and prognosis of cardiac amyloidosis: A systematic review and meta-analysis. Current problems in cardiology 2025. link 72 She J, Guo J, Sun Y, Chen Y, Zeng M, Ge M et al.. Predictive Model Based on Texture Analysis of Noncontrast Cardiac Magnetic Resonance Images for the Prognostic Evaluation of Cardiac Amyloidosis. Journal of computer assisted tomography 2025. link 73 Yamamoto M, Yamada Y, Sadahiro T, Sato K, Machino-Ohtsuka T, Murakoshi N et al.. Diagnostic Value of Combined Light and Electron Microscopic Examination in Endomyocardial Biopsy in Patients With Cardiac Amyloidosis. The Canadian journal of cardiology 2025. link 74 Chan N, Einstein AJ, Teruya S, Rodriguez C, Helmke S, Cuomo M et al.. The Impact of Active Ascertainment on Sex-Specific Differences in the Prevalence and Phenotype of Transthyretin Cardiac Amyloidosis: The Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations Study. The American journal of cardiology 2025. link 75 Hamon D, Landes R, Moulin T, Inamo J, Maupain C, Oghina S et al.. Predictive Value of Right Ventricular Sensing During Cardiac Device Implantation to Diagnose Cardiac Amyloidosis. JACC. Clinical electrophysiology 2025. link 76 Mengesha B, Small G, Paterson DI, Chow B. Transient ischemic dilatation in cardiac amyloidosis. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 2025. link 77 Noory N, Westin O, Maurer MS, Fosbøl E, Gustafsson F. Chest pain and coronary artery disease in cardiac amyloidosis: Prevalence, mechanisms, and clinical implications. American heart journal 2025. link 78 Stein-Merlob AF, Swier R, Vucicevic D. Evolving Strategies in Cardiac Amyloidosis: From Mechanistic Discoveries to Diagnostic and Therapeutic Advances. Cardiology clinics 2025. link 79 Blanco-López E, Martínez-Del Río J, López-Calles A, Negreira-Caamaño M, Águila-Gordo D, Soto-Martín P et al.. Cardiac amyloidosis and red flags: natural history and its impact in morbimortality. Medicina clinica 2025. link 80 Obi K, Bharwani S, Catalfamo V, Duran A, Baldawi H, Gillies C et al.. Prevalence and outcomes of concomitant cardiac amyloidosis and coronary artery disease. Current problems in cardiology 2025. link 81 Tang L, Zhao W, Li K, Tian L, Zhou X, Guo H et al.. Assessing microvascular dysfunction and predicting long-term prognosis in patients with cardiac amyloidosis by cardiovascular magnetic resonance quantitative stress perfusion. Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance 2025. link 82 Aimo A, Ferrari Chen YF, Castiglione V, Passino C, Genovesi D, Giorgetti A et al.. Positron emission tomography in cardiac amyloidosis: current evidence and future directions. Heart failure reviews 2025. link 83 Rojulpote C, Cuddy SAM, Kijewski MF, Dorbala S. Multimodality imaging approaches for diagnosis of cardiac amyloidosis. Progress in cardiovascular diseases 2025. link 84 Fontana M, Berk JL, Drachman B, Garcia-Pavia P, Hanna M, Lairez O et al.. Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis. Circulation. Heart failure 2025. link 85 Sun H, Zhang N, Liu X, Wang M, Wang L, Li Y. Concurrent light chain and transthyretin cardiac amyloidosis: A case report and review of the literature. Medicine 2025. link 86 Minamisawa M, Konishi H, Kitano Y, Abe H, Togo K, Izumiya Y. Patient Journey to Transthyretin Cardiac Amyloidosis Diagnosis　- A Japanese Claims Database Study. Circulation journal : official journal of the Japanese Circulation Society 2025. link 87 Nitsche C, Dobner S, Rosenblum HR, Patel KP, Longhi S, Yilmaz A et al.. Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis. European heart journal 2025. link 88 Lyle MA, Rosenthal JL, Nativi Nicolau JN, Leoni Moreno JC, Patel PC, Malik AA et al.. Heart Transplantation for Cardiac Amyloidosis: Mayo Clinic Consensus Statement. Mayo Clinic proceedings 2025. link 89 Aimo A, Milani P, Tini G, Vergaro G, Basset M, Musumeci B et al.. Neurohormonal therapies at baseline and follow-up and survival in wild-type transthyretin cardiac amyloidosis. Journal of cardiovascular medicine (Hagerstown, Md.) 2025. link 90 Longinow J, Mirzai S, Chen PH, Hanna M, Tang WHW. Skeletal muscle and subcutaneous fat quantity as prognostic indicators in cardiac amyloidosis. European journal of heart failure 2025. link 91 Müller ML, Brand A, Mattig I, Spethmann S, Messroghli D, Hahn K et al.. Myocardial Inflammation in Cardiac Transthyretin Amyloidosis: Prevalence and Potential Prognostic Implications. Circulation. Heart failure 2025. link 92 Bourguiba R, Antit S, Ben Rejab S, Bellakhal S, Zakhama L. Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) in Cardiac Amyloidosis: A Systematic Review. La Tunisie medicale 2025. link 93 Aimo A, Castiglione V, Tomasoni D, Bonfioli GB, Panichella G, Sinigiani G et al.. Gamma-glutamyltransferase independently predicts mortality and heart failure hospitalization in cardiac transthyretin amyloidosis. European journal of internal medicine 2025. link 94 Bourguiba R, Antit S, Ben Rejeb S, Bellakhal S, Zakhama L. Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) in Cardiac Amyloidosis: A Systematic Review: Study protocol. La Tunisie medicale 2025. link 95 Santo C, Romero C, Vaz Kerges Bueno B, Dabarian A, Nicolau JN, Fernandes F. Impact of sodium- glucose co-transporter 2 inhibitors in mortality and Decongestion in cardiac amyloidosis: A systematic review and meta-analysis. Current problems in cardiology 2025. link 96 Al Hazzouri A, Daou RM, Attieh P, Ibrahim Z, Ghadieh HE, Harbieh B. Navigating Diagnostic Ambiguities in Cardiac Amyloidosis: Insights from a Case with Delayed Diagnosis of AL Amyloidosis. The American journal of case reports 2025. link 97 Zampieri M, Del Franco A, Biagioni G, Tini G, Musumeci B, Barbato E et al.. The American College of Cardology/American Heart Association Heart Failure Staging System Highlights Diagnostic Delay and Predicts Outcome in Transthyretin Cardiac Amyloidosis. Mayo Clinic proceedings 2025. link 98 Ngouchet Nouhossi JL, Minga I, Szasz T, Truong VT, Johnson AE, Yang E et al.. Disparities in diagnosis and outcomes in American patients with transthyretin cardiac amyloidosis. The international journal of cardiovascular imaging 2025. link 99 Kato S, Misumi Y, Horita N, Yamamoto K, Utsunomiya D. Clinical Utility of Computed Tomography-Derived Myocardial Extracellular Volume Fraction: A Systematic Review and Meta-Analysis. JACC. Cardiovascular imaging 2024. link 100 Andrei V, Argirò A, Mazzoni C, Rossi G, Pieroni M, Bolognese L et al.. Screening for cardiac amyloidosis in patients with tenosynovial red flags: A collaboration between family medicine and cardiology. International journal of cardiology 2024. link

Original source

[1]
Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance. — Kittleson MM, Ambardekar AV, Cheng RK, Griffin JM, Maurer MS, Nativi-Nicolau J et al. Journal of the American College of Cardiology (2026)
[2]
Impact of disease-modifying therapies on imaging parameters in cardiac amyloidosis: A systematic review and meta-analysis. — Briasoulis A, Georgiopoulos G, Kourek C, Patras R, Lama N, Theodorakakou F et al. Current problems in cardiology (2026)
[3]
Ocular manifestations of transthyretin amyloidosis and their diagnostic value in cardiology: A comprehensive review. — Zhu Y, Gao S, Liu Q, Shen C Current problems in cardiology (2026)
[4]
Multiparametric CMR for detection of cardiac amyloidosis in patients with undifferentiated concentric left ventricular hypertrophy. — Quinn S, Zbihley A, Ramzan U, Raikar C, Engel J, Carr JC et al. The international journal of cardiovascular imaging (2026)
[5]
Complexities of Coexisting Cardiac Amyloidosis and Coronary Artery Disease: A Contemporary Review of Diagnostic and Treatment Approaches. — Lu Y, Bai G, Wang W, Li G Cardiology in review (2026)
[6]
Multimodality imaging for cardiac amyloidosis: clinical applications and future directions. — Sinigiani G, De Michieli L, Nistri S, Cecchin D, Mele D, Cipriani A European journal of internal medicine (2026)
[7]
Abdominal Fat Pad Fine-Needle Aspiration for the Diagnosis of Cardiac Amyloidosis: A Technical Note With Illustrative Images. — Mitrović N, Trifunović N, Nikolić M, Jašarović D, Stevanović D Diagnostic cytopathology (2026)
[8]
Multidisciplinary Management and the Role of Heart Failure Nurses in the Recognition and Treatment of Cardiac Amyloidosis. — Gast S, Enstrom C, Roberts A, Knipper E, Yacovino J, Brooksbank J The Journal of cardiovascular nursing (2026)
[9]
Advances in echocardiography for cardiac amyloidosis and restrictive cardiomyopathies. — Kafil TS, Canova TJ, Wang TKM, Klein AL Current opinion in cardiology (2026)
[10]
Left Bundle Branch Area Pacing for Cardiac Amyloidosis With Ser43Asn Mutant Transthyretin: A Case Report. — Yao F, Zhang D, Yang Z, Liu G, Wang P, Hu J et al. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026)
[11]
Artificial intelligence-driven longitudinal quantification of technetium pyrophosphate uptake in cardiac amyloidosis: Correlation with multimodality imaging and outcomes. — Miller RJ, Shanbhag A, Shahi K, Bosley D, Litwin L, White JA et al. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology (2026)
[12]
Diagnostic discordance between planar and single photon emission computed tomography cardiac scintigraphy for transthyretin cardiac amyloidosis. — Torres Ordonez A, Akincioglu C, Soman P, Kanitsorphan C, Adam A, Bobba A et al. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology (2026)
[13]
From pathophysiology to treatment in transthyretin cardiac amyloidosis. — Correia-Rodrigues Â, Ribeiro-Rodrigues T, Gonçalves L, Almeida JP, Ferreira MJ, Girao H Trends in molecular medicine (2026)
[14]
Basal inferoseptal longitudinal strain deformation may indicate early cardiac involvement in wild-type carpal ATTR. — Tsuruda T, Ota T, Terada T, Nakada H, Ogata M, Tanaka M et al. ESC heart failure (2026)
[15]
Cardiac Resynchronization Therapy Associated With Improved Survival in Advanced Transthyretin Cardiac Amyloidosis Despite Higher Disease Severity. — Huang J, Brown MT, Zhang K, Ahmed T, Zhang R, Merchant FM et al. The American journal of cardiology (2026)
[16]
Rationale and design of the imaging for detection rate of cardiac transthyretin amyloidosis study (the IMPACT study). — Beard E, Alos B, Khalifa B, Rosenberg T, Saulnier PJ, Boucher C et al. Archives of cardiovascular diseases (2026)
[17]
Trichrome, Congo red, and thioflavin S stains are comparable for the diagnosis of amyloid deposits in endomyocardial biopsies. — Burk J, Wein AN, Binkley MM, Duan X, Bernadt CT, Ritter JH et al. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology (2026)
[18]
Bio-Adrenomedullin Predicts Death and Major Adverse Cardiovascular Events in Cardiac Amyloidosis: A Cross-Continental Multicenter Study. — Müller ML, Knebel F, Hahn K, Schulte J, Arlt B, Hartmann O et al. Journal of the American Heart Association (2026)
[19]
Up-to-date review on heart transplantation and other advanced heart failure therapies in cardiac amyloidosis patients. — Lateef AU, Bilodeau-Gandre JL, Lyle MA Future cardiology (2026)
[20]
Safety and Efficacy of Left Atrial Appendage Occlusion in Cardiac Amyloidosis: A Single-Center Retrospective Study. — Mohamed AN, Chabaklo K, Alzahrani A, Alvarez P, Jaber W, Saliba W et al. Journal of cardiovascular electrophysiology (2026)
[21]
Comparative outcomes after atrial fibrillation catheter ablation in patients with cardiac amyloidosis: a multicenter propensity-matched analysis. — Mahmoud AK, Ibrahim R, Pham HN, Salih M, Lee JZ, Al Ahmad A et al. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing (2026)
[22]
Scintigraphy for transthyretin cardiac amyloidosis diagnosis in Austria, Germany, and Switzerland from 2021 to 2024. A survey report. — Lindner O, Bucerius J, Burchert B, Derlin T, Buechel RR European journal of nuclear medicine and molecular imaging (2026)
[23]
Estimated Stressed Blood Volume in Patients With Cardiac Amyloidosis. — Vanhentenrijk S, Augusto SN, Martens P, Ives L, Bhattacharya S, Carmona-Rubio A et al. The American journal of cardiology (2026)
[24]
Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation in Cardiac Amyloidosis. — Tan MC, Vignarajah A, Teo YS, Vigneswaramoorthy N, DeSimone CV, Deshmukh AJ et al. JACC. Clinical electrophysiology (2026)
[25]
Artificial Intelligence as a Prognostic Tool in Cardiac Amyloidosis: A Review. — Kong D, Capustin M, Ho M, Choi J, Stern DL, Hadley M et al. The American journal of cardiology (2026)
[26]
Evolving Strategies in Cardiac Amyloidosis: From Mechanistic Discoveries to Diagnostic and Therapeutic Advances. — Stein-Merlob AF, Swier R, Vucicevic D Heart failure clinics (2026)
[27]
Prevalence of amyloid deposition in patients undergoing surgical myectomy for presumed hypertrophic cardiomyopathy. — Katzianer DS, Kwon DH, Thamilarasan M, Finet JE, Jaber W, Desai M et al. Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology (2026)
[28]
Antemortem Underdiagnosis of Cardiac Amyloidosis in Sudden Cardiac Death Victims. — Ciliberti G, Westaby J, Finocchiaro G, Papadakis M, Behr ER, Sharma S et al. JACC. Clinical electrophysiology (2026)
[29]
Multi-chamber speckle-tracking imaging and prognostic utility of right atrial reservoir strain in light-chain cardiac amyloidosis. — Shi J, Wu B, Zhang Y, Yang J, Cui Y, Yu F et al. International journal of cardiology (2026)
[30]
Altered Myocardial Oxygenation and Impaired Energy Efficiency: A Pilot Study in Patients With Light Chain Cardiac Amyloidosis. — Dai L, Wang K, Li R, Qiao J, Berberet C, Huang Q et al. Journal of magnetic resonance imaging : JMRI (2026)
[31]
Additive diagnostic value of thoracic SPECT/CT imaging in perugini grade 1 patients who underwent bone scintigraphy. — Poledniczek M, Rettl R, Kronberger C, Schmid LM, Ermolaev N, Duca F et al. European journal of nuclear medicine and molecular imaging (2026)
[32]
Central nervous system involvement in cardiac amyloidosis: Redefining the heart-brain axis. — Giamundo DM, Cassataro G, Ministrini S, Stämpfli SF European journal of clinical investigation (2026)
[33]
CMR-derived skeletal muscle T1 time and extracellular volume as novel diagnostic markers for cardiac amyloidosis. — Kronberger C, Mascherbauer K, Poledniczek M, Schmid LM, Donà C, Koschutnik M et al. European journal of clinical investigation (2026)
[34]
Diagnostic practice points of multimodality imaging in cardiac amyloidosis: a summary of diagnostic perspective. — Rasheed R, Mutawa AM, Numani SP, Masud A, Shahid M, Maher AM et al. Nuclear medicine communications (2026)
[35]
Evaluating natural history and treatment response in cardiac amyloidosis: the evolving role of multimodality imaging. — Walser A, Gräni C, Stämpfli SF, Cuddy SAM, Clerc OF, Pabón AJR et al. European heart journal. Cardiovascular Imaging (2026)
[36]
Atrial and ventricular arrhythmias in patients with cardiac amyloidosis: Incidence, risk factors, and prognostic implications. — Li JZ, Oates CP, Njus M, Barish R, O'Donoghue S, Sheikh FH Cardiovascular revascularization medicine : including molecular interventions (2026)
[37]
Left ventricular wall thickness and derived parameters in cardiac amyloidosis. — Chedid El Helou M, Finet JE, Kassab J, El Dahdah J, Carmona Rubio A, Kanta A et al. Progress in cardiovascular diseases (2026)
[38]
Exploring the MicroRNA Landscape in Cardiac Amyloidosis: Molecular Insights and Clinical Applications. — Kontaraki JE, Plevritaki A, Sallo A, Fragkiadakis K, Kallergis E, Zacharis E et al. Genes (2026)
[39]
Global Longitudinal Strain for Prognostic Staging in Wild-Type Transthyretin Cardiac Amyloidosis. — Debonnaire P, L'Hoyes W, Donal E, Verheyen N, Vervloet D, Dujardin K et al. Circulation. Cardiovascular imaging (2026)
[40]
Outcomes and predictors of atrial fibrillation in cardiac amyloidosis. — Rehman WU, Alam I, Shah T, Zahir J, Khan MS, Khalil H et al. Medicine (2026)
[41]
Free-Breathing Multi-Slice Co-Registered Cardiac T1, T2, and ADC Mapping With Spin-Echo Echo Planar Imaging. — Mai D, Kara D, Liu Y, Moura TRS, Sadighi M, Kanj F et al. Magnetic resonance in medicine (2026)
[42]
Prevalence of frailty in cardiac transthyretin amyloidosis: A systematic review and meta-analysis. — Finazzi A, Esposito E, Riva C, Mangili E, Lodovici L, Bruni AA et al. Ageing research reviews (2026)
[43]
Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis. — Zampieri M, Biagioni G, Del Franco A, Canepa M, Porto I, Zanoletti M et al. Circulation. Heart failure (2026)
[44]
Testing the utility of the first step of system evaluation theory in creating a system map of care for cardiac amyloidosis early detection: A case study. — Ball SL, Koskan A, Guzman J, Dev S PloS one (2026)
[45]
Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association. — Garcia-Pavia P, Gonzalez-Lopez E, Anderson LJ, Cappelli F, Damy T, Fontana M et al. European heart journal (2026)
[46]
Prognostic value of heart failure hospitalization in transthyretin cardiac amyloidosis: an international cohort study. — Laenens D, Debonnaire P, De Smet MAJ, Pinto F, Brito D, Droogmans S et al. ESC heart failure (2026)
[47]
Navigating the Lead Paradox: Successful Co-Implantation of Cardiac Contractility Modulation Device and a Micra Leadless Pacemaker. — Pavani G, Garrone P, Varalda G, Previti A, Bianco M, Chinaglia A Journal of cardiovascular electrophysiology (2026)
[48]
Optimizing drug therapies in cardiac amyloidosis. — Younis M, Ogbu I, Kalra DK Pharmacology & therapeutics (2025)
[49]
Echocardiographic index of left ventricular performance for prognostication in transthyretin cardiac amyloidosis: the central role of stroke volume index. — Serenelli M, Cantone A, Dal Passo B, Sanguettoli F, Fabbri G, Guidi Colombi G et al. Journal of cardiovascular medicine (Hagerstown, Md.) (2025)
[50]
Comparative Outcomes and Cardiac Imaging Features in Light Chain Versus Transthyretin Cardiac Amyloidosis: A Multicenter Retrospective Cohort Study. — Mahmood H, Kato JA The American journal of cardiology (2025)
[51]
Predictors of Early Death in Patients With Wild-Type Transthyretin Cardiac Amyloidosis. — Milani P, Sanna GD, Mussinelli R, Basset M, Guida G, Attanasio A et al. Journal of the American Heart Association (2025)
[52]
Coronary Artery Disease and Microvascular Ischemia in Patients with Cardiac Amyloidosis. — Itzhaki Ben Zadok O, Vaxman I, Hoss S, Talmor-Barkan Y, Steinmetz T, Raanani P et al. Acta haematologica (2025)
[53]
Transthyretin Cardiac Amyloidosis in Australia and New Zealand-A Multi-Site Snapshot for 2022. — Geenty P, Davidson N, Gorrie N, Bart N, Baumwol J, Sutton T et al. Heart, lung & circulation (2025)
[54]
Recovery of right ventricular function in patients with transthyretin cardiac amyloidosis after one-year tafamidis administration. — Nagai T, Horinouchi H, Hashimoto K, Ijichi T, Yoshioka K, Ikari Y The international journal of cardiovascular imaging (2025)
[55]
Predictors of mortality by an artificial intelligence enhanced electrocardiogram model for cardiac amyloidosis. — Amadio JM, Grogan M, Muchtar E, Lopez-Jimenez F, Attia ZI, AbouEzzeddine O et al. ESC heart failure (2025)
[56]
Prognosis of patients with wild-type transthyretin cardiac amyloidosis and non-sustained ventricular tachycardia. — Sehrawat O, Swain WH, Alcantara HP, Tan NY, Abou Ezzeddine OF, Grogan M et al. Journal of cardiovascular electrophysiology (2025)
[57]
The Mayo ATTR-CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis. — Bonfioli GB, Tomasoni D, Vergaro G, Castiglione V, Adamo M, Fabiani I et al. European journal of heart failure (2025)
[58]
Prognostic Value of Baseline and Soluble ST2 Change in Patients With Light Chain Cardiac Amyloidosis. — Xin A, Li X, Huang Y, Zhou Q, Zhuang X, Liu H et al. Journal of the American Heart Association (2025)
[59]
Single-center analysis of cardiac amyloidosis using 99m Tc-HMDP imaging for diagnosis and evaluation after tafamidis treatment. — Egi R, Matsusaka Y, Watanabe K, Seto A, Matsunari I, Arai T et al. Nuclear medicine communications (2025)
[60]
Progression and prognostic significance of electrocardiographic findings in patients with cardiac amyloidosis. — Argirò A, Zampieri M, Mazzoni C, Fumagalli C, Baccini M, Mattei A et al. ESC heart failure (2025)
[61]
Amyloid Deposition Mainly Localized in the Basal Area of the Left Ventricle in a Patient with Amyloid Transthyretin Cardiac Amyloidosis. — Iwasaki R, Kawano H, Fukui K, Otsuka K, Arakawa S, Takei A et al. Internal medicine (Tokyo, Japan) (2025)
[62]
Prevalence of cardiac amyloidosis in atrial fibrillation: a CMR study prior to catheter ablation. — Azuma M, Kato S, Sawamura S, Fukui K, Takizawa R, Nakayama N et al. Heart and vessels (2025)
[63]
Prevalence of Cardiac Amyloidosis Among Elderly Patients With Recent-Onset Atrial Fibrillation: The PREVAL-ATTR Study. — Remior-Pérez P, Gómez-Molina M, García-Rodríguez D, Gallego-Delgado M, Mohamed-Salem L, de Haro-Del Moral J et al. The Canadian journal of cardiology (2025)
[64]
Cardiac amyloidosis: when to suspect and how to confirm. — Emdin M, Aimo A, Ferrari Chen YF, Merlo M, Porcari A, Vergaro G et al. Journal of cardiovascular medicine (Hagerstown, Md.) (2025)
[65]
Cardiovascular outcomes of patients with atrial fibrillation and concomitant cardiac amyloidosis undergoing percutaneous catheter ablation. — Shamaki GR, Neppala S, Hidri S, Hotwani P, Aldabagh M, Aziz S et al. Current problems in cardiology (2025)
[66]
Wild-type transthyretin cardiac amyloidosis and aortic stenosis: Can carpal tunnel syndrome help distinguish the chicken from the egg? — Delbarre MA, Chadha GD, Annabi MS, Nouri R, Zaroui A, Blanc-Durand P et al. Journal of internal medicine (2025)
[67]
Leveraging a Vision Transformer Model to Improve Diagnostic Accuracy of Cardiac Amyloidosis With Cardiac Magnetic Resonance. — Cockrum J, Nakashima M, Ammoury C, Rizkallah D, Mauch J, Lopez D et al. JACC. Cardiovascular imaging (2025)
[68]
Tafamidis Reduces Death and Hospitalization for Acute Heart Failure in Octogenarian Patients With Transthyretin Cardiac Amyloidosis: A Propensity Score-Weighted Cohort Study. — Zmuda L, Zaroui A, Kharoubi M, Boutin E, Roca F, Oghina S et al. Journal of the American Heart Association (2025)
[69]
Effect of tafamidis therapy on physical function in patients with wild-type transthyretin cardiac amyloidosis. — Shibata A, Izumiya Y, Yoshida T, Tanihata A, Kitada R, Otsuka K et al. Journal of cardiology (2025)
[70]
Right ventricular coupling predicts cardiopulmonary fitness in cardiac transthyretin amyloidosis. — Knoll K, Gross S, Fuchs P, Erben A, Hock J, von Scheidt M et al. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis (2025)
[71]
Role of biomarkers in early diagnosis and prognosis of cardiac amyloidosis: A systematic review and meta-analysis. — Albulushi A, Buraiki JA, Aly G, Al-Wahshi Y, Jahangirifard A Current problems in cardiology (2025)
[72]
Predictive Model Based on Texture Analysis of Noncontrast Cardiac Magnetic Resonance Images for the Prognostic Evaluation of Cardiac Amyloidosis. — She J, Guo J, Sun Y, Chen Y, Zeng M, Ge M et al. Journal of computer assisted tomography (2025)
[73]
Diagnostic Value of Combined Light and Electron Microscopic Examination in Endomyocardial Biopsy in Patients With Cardiac Amyloidosis. — Yamamoto M, Yamada Y, Sadahiro T, Sato K, Machino-Ohtsuka T, Murakoshi N et al. The Canadian journal of cardiology (2025)
[74]
The Impact of Active Ascertainment on Sex-Specific Differences in the Prevalence and Phenotype of Transthyretin Cardiac Amyloidosis: The Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations Study. — Chan N, Einstein AJ, Teruya S, Rodriguez C, Helmke S, Cuomo M et al. The American journal of cardiology (2025)
[75]
Predictive Value of Right Ventricular Sensing During Cardiac Device Implantation to Diagnose Cardiac Amyloidosis. — Hamon D, Landes R, Moulin T, Inamo J, Maupain C, Oghina S et al. JACC. Clinical electrophysiology (2025)
[76]
Transient ischemic dilatation in cardiac amyloidosis. — Mengesha B, Small G, Paterson DI, Chow B Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology (2025)
[77]
Chest pain and coronary artery disease in cardiac amyloidosis: Prevalence, mechanisms, and clinical implications. — Noory N, Westin O, Maurer MS, Fosbøl E, Gustafsson F American heart journal (2025)
[78]
Evolving Strategies in Cardiac Amyloidosis: From Mechanistic Discoveries to Diagnostic and Therapeutic Advances. — Stein-Merlob AF, Swier R, Vucicevic D Cardiology clinics (2025)
[79]
Cardiac amyloidosis and red flags: natural history and its impact in morbimortality. — Blanco-López E, Martínez-Del Río J, López-Calles A, Negreira-Caamaño M, Águila-Gordo D, Soto-Martín P et al. Medicina clinica (2025)
[80]
Prevalence and outcomes of concomitant cardiac amyloidosis and coronary artery disease. — Obi K, Bharwani S, Catalfamo V, Duran A, Baldawi H, Gillies C et al. Current problems in cardiology (2025)
[81]
Assessing microvascular dysfunction and predicting long-term prognosis in patients with cardiac amyloidosis by cardiovascular magnetic resonance quantitative stress perfusion. — Tang L, Zhao W, Li K, Tian L, Zhou X, Guo H et al. Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance (2025)
[82]
Positron emission tomography in cardiac amyloidosis: current evidence and future directions. — Aimo A, Ferrari Chen YF, Castiglione V, Passino C, Genovesi D, Giorgetti A et al. Heart failure reviews (2025)
[83]
Multimodality imaging approaches for diagnosis of cardiac amyloidosis. — Rojulpote C, Cuddy SAM, Kijewski MF, Dorbala S Progress in cardiovascular diseases (2025)
[84]
Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis. — Fontana M, Berk JL, Drachman B, Garcia-Pavia P, Hanna M, Lairez O et al. Circulation. Heart failure (2025)
[85]
Concurrent light chain and transthyretin cardiac amyloidosis: A case report and review of the literature. — Sun H, Zhang N, Liu X, Wang M, Wang L, Li Y Medicine (2025)
[86]
Patient Journey to Transthyretin Cardiac Amyloidosis Diagnosis　- A Japanese Claims Database Study. — Minamisawa M, Konishi H, Kitano Y, Abe H, Togo K, Izumiya Y Circulation journal : official journal of the Japanese Circulation Society (2025)
[87]
Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis. — Nitsche C, Dobner S, Rosenblum HR, Patel KP, Longhi S, Yilmaz A et al. European heart journal (2025)
[88]
Heart Transplantation for Cardiac Amyloidosis: Mayo Clinic Consensus Statement. — Lyle MA, Rosenthal JL, Nativi Nicolau JN, Leoni Moreno JC, Patel PC, Malik AA et al. Mayo Clinic proceedings (2025)
[89]
Neurohormonal therapies at baseline and follow-up and survival in wild-type transthyretin cardiac amyloidosis. — Aimo A, Milani P, Tini G, Vergaro G, Basset M, Musumeci B et al. Journal of cardiovascular medicine (Hagerstown, Md.) (2025)
[90]
Skeletal muscle and subcutaneous fat quantity as prognostic indicators in cardiac amyloidosis. — Longinow J, Mirzai S, Chen PH, Hanna M, Tang WHW European journal of heart failure (2025)
[91]
Myocardial Inflammation in Cardiac Transthyretin Amyloidosis: Prevalence and Potential Prognostic Implications. — Müller ML, Brand A, Mattig I, Spethmann S, Messroghli D, Hahn K et al. Circulation. Heart failure (2025)
[92]
Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) in Cardiac Amyloidosis: A Systematic Review. — Bourguiba R, Antit S, Ben Rejab S, Bellakhal S, Zakhama L La Tunisie medicale (2025)
[93]
Gamma-glutamyltransferase independently predicts mortality and heart failure hospitalization in cardiac transthyretin amyloidosis. — Aimo A, Castiglione V, Tomasoni D, Bonfioli GB, Panichella G, Sinigiani G et al. European journal of internal medicine (2025)
[94]
Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) in Cardiac Amyloidosis: A Systematic Review: Study protocol. — Bourguiba R, Antit S, Ben Rejeb S, Bellakhal S, Zakhama L La Tunisie medicale (2025)
[95]
Impact of sodium- glucose co-transporter 2 inhibitors in mortality and Decongestion in cardiac amyloidosis: A systematic review and meta-analysis. — Santo C, Romero C, Vaz Kerges Bueno B, Dabarian A, Nicolau JN, Fernandes F Current problems in cardiology (2025)
[96]
Navigating Diagnostic Ambiguities in Cardiac Amyloidosis: Insights from a Case with Delayed Diagnosis of AL Amyloidosis. — Al Hazzouri A, Daou RM, Attieh P, Ibrahim Z, Ghadieh HE, Harbieh B The American journal of case reports (2025)
[97]
The American College of Cardology/American Heart Association Heart Failure Staging System Highlights Diagnostic Delay and Predicts Outcome in Transthyretin Cardiac Amyloidosis. — Zampieri M, Del Franco A, Biagioni G, Tini G, Musumeci B, Barbato E et al. Mayo Clinic proceedings (2025)
[98]
Disparities in diagnosis and outcomes in American patients with transthyretin cardiac amyloidosis. — Ngouchet Nouhossi JL, Minga I, Szasz T, Truong VT, Johnson AE, Yang E et al. The international journal of cardiovascular imaging (2025)
[99]
Clinical Utility of Computed Tomography-Derived Myocardial Extracellular Volume Fraction: A Systematic Review and Meta-Analysis. — Kato S, Misumi Y, Horita N, Yamamoto K, Utsunomiya D JACC. Cardiovascular imaging (2024)
[100]
Screening for cardiac amyloidosis in patients with tenosynovial red flags: A collaboration between family medicine and cardiology. — Andrei V, Argirò A, Mazzoni C, Rossi G, Pieroni M, Bolognese L et al. International journal of cardiology (2024)

Share:Twitter Reddit LinkedIn